One week after Takeda walked away, Finch faces second round of layoffs, pipeline pruning

Finch may be an inch underground at this point.

Somerville, MA-based Finch Therapeutics has had a rough year, starting with the FDA slapping a clinical hold on its late-stage C. difficile treatment in March. While that hold was lifted at the end of April, it had already taken its toll, with Finch laying off 37 of its workers and cutting its hepatitis B program in the interim.